Kodiak Sciences Stock Jumps 90% on Positive Phase 3 AMD Data: What Traders Should Watch Next
Kodiak Sciences shares surged as much as 90% premarket after positive Phase 3 AMD data. Here is what traders may watch next.
Zymeworks Updates 2026 Guidance After Finalizing Theravance Biopharma Deal
Zymeworks has updated its 2026 guidance after finalizing its Theravance Biopharma acquisition, giving investors a clearer post-merger framew…
Kodiak Sciences’ KOD Stock Jumps 65% After DAYBREAK Phase 3 Success
Kodiak Sciences shares reached $54.42 in premarket trading after DAYBREAK met primary endpoints for two eye-treatment candidates.
AbbVie’s Parkinson’s Drug Approval Gives ABBV Stock a New October Catalyst
FDA approval for Juvmo gives AbbVie a potential post-Humira growth catalyst ahead of its planned October 2026 U.S. launch.
Mirum’s FDA Approval Puts Rare-Disease Potential in the Spotlight
Mirum Pharmaceuticals’ FDA approval for a rare bone disorder could become an important catalyst for the smaller biopharma company.
Outlook Therapeutics Faces a Second FDA Rejection for ONS-5010
A second Complete Response Letter puts renewed focus on the uncertainty of binary FDA decisions for small-cap biotechnology companies.
Moderna-Merck Cancer Vaccine Trial Success Gives Investors a New Oncology Catalyst
Moderna and Merck cleared a major Phase 3 hurdle, strengthening the case for individualized cancer vaccines and renewed pipeline attention.
Merck’s Oncology Approval Fuels Debate Over a Potential 37% Valuation Discount
Merck’s Welireg-Lenvima approval adds an oncology catalyst as investors weigh a DCF-based 37% undervaluation claim and Keytruda patent-cliff…
Mirum Shares Gain as FDA Approval Validates Rare-Disease Drug Strategy
Mirum shares rose 1.0% to $90.23 as FDA approval transformed a key regulatory question into a confirmed catalyst for Nasdaq-listed MIRM.
Eli Lilly Expands Olumiant Reach With FDA Approval for Adolescent Alopecia
FDA approval for adolescent alopecia broadens Olumiant’s reach and reinforces Eli Lilly’s immunology strategy beyond GLP-1 drugs.
Merck Wins FDA Approval for Welireg-Lenvima Combination in Advanced Kidney Cancer
Merck’s Welireg-Lenvima approval expands its oncology portfolio and may influence long-term revenue models as patent-cliff risks loom.
Grail Stock Jumps 55% After FDA Panel Supports Multi-Cancer Detection Test
Grail shares surged 55% through Friday morning after a favorable FDA advisory vote on its multi-cancer early detection test.